You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

17 search results for: disease background

The Burden of Atopic Dermatitis in Children – The Impact of Persistent <b>Disease</b>

expert video

The Burden of Atopic Dermatitis in Children – The Impact of Persistent Disease

1 min

Dermatology

Dr. Mark Koh explains how age at disease onset is linked to persistent disease.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

Why targeting Type 2 Inflammation is important in the treatment of skin <b>disease</b>s like AD, PN and CSU

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

<b>Disease</b>-Specific Aspects of Itch in AD, PN, and CSU

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Atopic Dermatitis (AD) is a Type 2 Inflammatory <b>Disease</b>

videoanimation

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease

2 min

Dermatology

Discover the pathophysiological mechanisms involved in atopic dermatitis.

expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

2 min

Dermatology

Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.

expert video

Evolving Topics in Type 2 Inflammation

49 min

Type 2 Inflammation

Drs. Eric Simpson, Jonathan Spergel, and Profs. Francesca Puggioni, Ian Pavord, Peter Hellings discuss emerging topics in type 2 inflammatory diseases

expert video

What Are the Key Inflammatory Processes in Patients with COPD?

2 min

Pulmonology

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.

expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

5 min

Dermatology

Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.

expert video

Can early intervention modify the course of AD?

5 min

Dermatology

Dr. Amy Paller emphasizes that early intervention in children can alter disease progression. Depending on the severity, this can be achieved with topical interventions or systemic therapies.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

expert video

Diagnostic Considerations: Coexistence, and Distinctions of AD & PN

3 min

Dermatology

Dr. Mark Tang talks about the coexistence of AD and PN and considerations for choosing treatment.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region